Bayer takes another shot at Monsanto acquisition
pharmafile | September 6, 2016 | News story | Manufacturing and Production, Sales and Marketing |ย ย Bayer, acqusition, monsantoย
Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort to snare the agrochemical and agricultural biotech.
The German chemical company says it is now prepared to pay $127.50 per share, 2% more than its previous bid, bringing its total valuation of the company to approximately $56 billion, or $65 billion including debt. The offer falls short of some analyst predictions on how much the company will have to venture to secure the deal, with some placing the sweet spot at $135 a share.
Monsantoโs shares have declined since Bayerโs initial bid, and closed at $107.44 in New York on Friday.
Matt Fellows
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Third application for Orionโs prostate cancer drug submitted by partner Bayer
Finnishย pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …

Bayer and Evotec to collaborate on precision cardiology
Bayer and Evotec have announced that they have updated the focus of their collaboration to …






